Beyond weight loss- tirzepatide as a dual GIP:GLP-1 receptor agonist for obstruc
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been FDA-approved for treating moderate-to-severe OSA in obese adults. It significantly reduces AHI and improves sleep quality.
Dietary Fiber and Glucagon-Like Peptide-1 Receptor Agonists in Obesity Managemen
GLP-1 receptor agonists and dietary fibers converge on the gut-brain axis, offering complementary benefits. This review examines their synergies and potential interactions in weight loss and maintenance.
Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Ca
Semaglutide 2.4 mg significantly lowers the risk of heart attacks, strokes, and mortality in ASCVD patients with overweight or obesity. This study highlights its broad benefits beyond diabetes management.
Cannabidiol Reduces Early-Stage Inflammation in Rat Adipose Tissue
This CBD obesity inflammation study investigates cannabidiol's impact on fat tissue inflammation in rats. The research highlights CBD's potential to reduce lipid accumulation and inflammatory markers. Findings suggest tissue-specific effects in visceral…
Cannabidiol & Glucose Tolerance: Clinical Trial Evidence
Clinical Takeaway In this pilot study, short-term low-dose CBD supplementation did not improve glucose tolerance or meaningfully alter the gut microbiome in sedentary adults with overweight or obesity. While animal studies and epidemiological data have…
Cannabinoid Clinical Trials: CBD, Glucose & Gut Health
This article reviews cannabinoid clinical trials CBD glucose effects on metabolic health. Short-term low-dose CBD supplementation showed no significant improvements in glucose tolerance or gut microbiome. These findings highlight the need for further…
Cannabidiol & Glucose Tolerance: Clinical Research Review
This article reviews cannabidiol glucose tolerance clinical trial findings in sedentary adults with overweight or obesity. The study found no significant improvements in glucose tolerance or gut microbiome with low-dose CBD. These findings highlight the…
Endocannabinoid System Clinical Research: CBD & Metabolism Analysis
This cannabidiol glucose tolerance clinical research evaluates the impact of low-dose CBD supplementation on metabolic health. The study found no significant improvements in glucose tolerance or gut microbiome composition. These findings highlight the…
How N-Acylethanolamines Control Appetite, Energy Balance, and Metabolic Health
N-acylethanolamines appetite regulation plays a crucial role in controlling energy balance and metabolic health. These lipid signaling molecules influence cannabinoid receptor pathways that affect appetite and metabolism. Understanding…
Popular Weight-Loss Drugs May Also Treat Addiction – SciTechDaily
GLP-1 receptor agonist addiction research suggests these drugs may reduce substance use disorders while aiding weight loss. This dual benefit offers promising clinical implications. However, further trials are needed to confirm these findings.